| Abstract: |
With the completion of human genome project, the confluence of information on drivers of cell proliferation and the emergence of technology to define and produce therapeutics, molecularly targeted therapies are beginning to be integrated into the overall treatment of patients with cancer. This chapter focuses on the development, mechanism of action, and clinical utility of these agents in breast cancer. Monoclonal antibodies (trastuzumab, bevacizumab, and cetiximab), small molecule tyrosine kinase and farnesyl transferase inhibitors (gefitinib, erlotinib, lapatinib, and tipifarnib), mammalian target of rapamycin and Raf kinase inhibitors (temsirolimus, everolimus, and sorafenib), and other novel agents (ZD 6474, SU 11248) are discussed. In addition, the use of molecular taxonomy and microarray analysis in predicting outcomes and response to therapy are reviewed. |
